Quintrio
Home

FINANCE SERVICES

GPGI, Inc.

GPGI

GPGI Inc is a diversified holding permanent capital platform designed to acquire, own, and scale high-quality businesses that hold great positions in good industries.

Last trade $13.00
Day change -$0.51 (-3.77%)
Day range $12.70 – $13.76
Volume 791,558
Market cap $3.92B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.92B
Price / earnings
—
Price / book
1.2×
Price / sales
—
EV / sales
—
EV / EBITDA
-50.15×

Profitability

Earnings per share
-$0.23
Return on assets
-1.84%
Return on equity
-2.01%
Dividend yield
0.06%

Liquidity and leverage

Debt / equity
0×
Current ratio
0.94×
Quick ratio
0.94×
Cash ratio
0.24×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$59.49M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for GPGI, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026
Revenue$0$0$0
Cost of revenue$0$0$0
Gross profit$0$0$0
Selling, general and administrative$5.8M$9.4M$55.6M
Research and development$0$0$0
Total operating expenses$5.8M$9.4M$55.6M
Operating income-$5.8M-$9.4M-$55.6M
Interest expense$0$0$0
Income before taxes-$5.8M-$15.6M-$77.3M
Income taxes-$7M$1.2M$3.6M
Net income$76M$50.3M-$235M
Net income attributable to common shareholders$76M$50.3M-$235M
EBITDA-$5.8M-$9.4M-$55.6M
Basic earnings per share$0.26$0.17-$0.87
Diluted earnings per share$0.26$0.17-$0.87

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Carlisle Exhibits Strong Prospects Despite Persisting Headwinds

Carlisle Companies (CSL) reported 8% revenue growth in its Construction Materials segment and 10% growth in Weatherproofing Technologies in Q2 2026, driven by strong re-roofing demand and market-share gains. However, elevated petroleum-based raw material and freight costs, exacerbated by Middle East geopolitical tensions, pressured margins as cost of sales increased 10.3%. The company raised its share repurchase target to $1.2 billion and increased its quarterly dividend by 14%, marking its 50th consecutive annual dividend increase.

Zacks Investment Research

Here's Why It is Appropriate to Invest in ITT Stock Right Now

ITT Inc. (ITT) is well-positioned for near-term growth driven by strength across its Flow Technologies, Connect and Control Technologies, and Motion Technologies segments. The company's recent acquisitions of Aerospace Contacts and SPX FLOW are expanding capabilities, while continued innovation investments and shareholder rewards through dividends and buybacks support its investment appeal. ITT carries a Zacks Rank #2 (Buy) rating.

Zacks Investment Research

Zacks Industry Outlook Grupo Cibest, POSCO, Griffon and GPGI

The Zacks Diversified Operations industry is experiencing solid momentum driven by manufacturing sector strength, robust aerospace and defense markets, and commercial aviation growth. However, supply-chain disruptions remain a concern. The industry ranks #59 among 247 Zacks industries but has underperformed the S&P 500 by 28.2% over the past year. Four stocks are highlighted as leaders: Grupo Cibest, POSCO Holdings, Griffon Corp, and GPGI Inc.

GlobeNewswire Inc.

GPGI, CMPO IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GPGI, Inc. f/k/a CompoSecure, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 14 Deadline in Securities Class Action – GPGI, CMPO

Rosen Law Firm is notifying investors in GPGI, Inc. (formerly CompoSecure, Inc.) of a September 14, 2026 deadline to serve as lead plaintiff in a securities class action lawsuit. The lawsuit alleges that defendants made materially false and misleading statements regarding the Husky acquisition, including overstating its value, misrepresenting revenue targets, and prioritizing fees for Resolute Holdings over shareholder value creation.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN

Pomerantz Law Firm has filed class action lawsuits against Regeneron Pharmaceuticals, Capricor Therapeutics, and GPGI, Inc. for alleged securities fraud. The primary focus is on Regeneron, where a Phase III clinical trial for Fianlimab-Libtayo failed to meet its primary endpoint, causing the stock to decline significantly on two separate occasions in April and May 2026. Investors with losses are urged to contact the firm by September 14, 2026, to potentially become lead plaintiffs.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.0025 per share
Declared
Nov 4, 2026
Ex-dividend
Nov 18, 2026
Pay date
Dec 1, 2026
Ex-dividendAmount / sharePay dateType
Aug 17, 2026$0.0025Sep 1, 2026recurring
May 18, 2026$0.0025Jun 1, 2026recurring
Feb 13, 2026$0.0025Feb 27, 2026recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.